Home › Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement
 

Keywords :   


Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement

2013-02-20 13:00:00| Merck.com - Corporate News

Dateline City:  WHITEHOUSE STATION, N.J. & SEOUL, South Korea WHITEHOUSE STATION, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--Merck, (NYSE: MRK) known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., entered into an agreement to develop and commercialize multiple pre-specified and undisclosed biosimilar candidates. Language:  English Contact HTML:  Merck Media Relations:Ronald Rogers, 908-423-6449orMerck Investor Relations:Justin Holko, 908-423-5088orSamsung Bioepis:HongSeok Ji, +82-32-455-6102 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: enter development agreement samsung

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Registration Now Open for RadTech 2025
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 7A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
More »